Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
DUBLIN, April 27, 2023 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of Vyxeos® (daunorubicin and cytarabine).
Vyxeos (JZP351/CPX315) Presentations
|
Presentation Title |
Author |
Presentation Details |
|
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study |
Ritchie, K. et al. |
Type: Poster Session Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 5, 2023 (8:00 -11:00 a.m. CT) Abstract number: 7027 |
|
Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia
|
Mitchell, J.D. et al. |
Type: Poster Session Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 5, 2023 (8:00 -11:00 a.m. CT) Abstract number: 7029 |
|
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia [Jazz-Supported IST] |
Park, S. et al. |
Type: Poster Session Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 5, 2023 (8:00 -11:00 a.m. CT) Abstract number: 7024 |